Beginners

Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast

Source Motley_fool

Pfizer (NYSE:PFE), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 million shares, almost 60% above its three-month average.

How the markets moved today

Tuesday’s move followed Pfizer's announcement trimming 2025–2026 revenue expectations and highlighting faster COVID-19 erosion. Investors will watch to see whether new products and deals can restore earnings growth.

The S&P 500 (SNPINDEX:^GSPC) slipped 0.26% to 6,799, while the Nasdaq Composite (NASDAQINDEX:^IXIC) added 0.23% to finish at 23,111. Pfizer’s commentary impacted its industry peers as well. Merck (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) fell 1.99% and 2.27%, respectively, as investors reassessed large pharma earnings power.

What this means for investors

Pfizer cut its 2025 revenue guidance from to $62 billion, down from between $61 billion and $64 billion. It reaffirmed its 2025 adjusted EPS of $3.00 - $3.15.

It told investors it is expecting flat growth for 2026, with anticipated revenues between $59.5 billion and $62.5 billion. This is down to falling revenue from COVID drugs and expiring patents.

The company said it is cutting costs and investing the proceeds into R&D. For example, it recently acquired a biopharmaceutical company focused on obesity and cardiometabolic diseases. It will push ahead with obesity drug trials in 2026. However, it could take time for newer initiatives to bear fruit.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 962%* — a market-crushing outperformance compared to 193% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of December 16, 2025.

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

US Dollar's Decline Predicted in 2026: Morgan Stanley's Outlook on Currency Volatility Morgan Stanley forecasts a 5% drop in the dollar by mid-2026, attributed to continued Fed rate cuts. A recovery may follow as growth improves and funding currency dynamics shift favorably toward the euro and Swiss franc.

Author Mitrade

Nov 25, Tue

Morgan Stanley forecasts a 5% drop in the dollar by mid-2026, attributed to continued Fed rate cuts. A recovery may follow as growth improves and funding currency dynamics shift favorably toward the euro and Swiss franc.

Gold's Historic 2025 Rally: Can the Momentum Last Through 2026?Following a historic surge in 2025 that saw prices climb over 60% and break records more than 50 times, gold investors are now looking ahead to assess whether the precious metal can sustain its momentum into 2026. Despite outperforming most major asset classes and heading for its best annual performance since 1979, analysts are divided on the outlook—with some seeing further room for gains and others cautioning that risks are rising.

Author Mitrade

Dec 09, Tue

Following a historic surge in 2025 that saw prices climb over 60% and break records more than 50 times, gold investors are now looking ahead to assess whether the precious metal can sustain its momentum into 2026. Despite outperforming most major asset classes and heading for its best annual performance since 1979, analysts are divided on the outlook—with some seeing further room for gains and others cautioning that risks are rising.

XRP Spot ETFs Notch 30 Straight Days of Inflows, Bucking Wider Crypto Trend Since their debut on November 13, U.S.-listed spot exchange-traded funds (ETFs) for XRP have recorded net inflows for 30 consecutive trading days, a steady performance that stands in contrast to the more volatile flows seen in larger bitcoin and ether funds.

Author Mitrade

Dec 15, Mon

Since their debut on November 13, U.S.-listed spot exchange-traded funds (ETFs) for XRP have recorded net inflows for 30 consecutive trading days, a steady performance that stands in contrast to the more volatile flows seen in larger bitcoin and ether funds.

Global Markets on Edge Ahead of Key Economic Data and Central Bank Decisions As investors remain cautious, focus turns to upcoming UK wage data and European manufacturing insights ahead of crucial interest rate discussions. Market sentiment reflects heightened risk aversion amid U.S. jobs report anticipation.

Author Mitrade

18 hours ago

As investors remain cautious, focus turns to upcoming UK wage data and European manufacturing insights ahead of crucial interest rate discussions. Market sentiment reflects heightened risk aversion amid U.S. jobs report anticipation.

Cryptocurrencies Extend Losses as Year-End Caution and Thinning Liquidity Weigh on Market The cryptocurrency market declined on Monday, mirroring a pullback in global risk assets as investors turned cautious ahead of key U.S. economic data. The broad-based retreat highlighted thinning liquidity and growing risk aversion across financial markets as the year draws to a close.

Author Mitrade

16 hours ago

The cryptocurrency market declined on Monday, mirroring a pullback in global risk assets as investors turned cautious ahead of key U.S. economic data. The broad-based retreat highlighted thinning liquidity and growing risk aversion across financial markets as the year draws to a close.

Popular Symbols